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Abstract 
Background: Adrenal suppression (AS), a glucocorticoid (GC) side effect associated with significant morbidity, is 
well described related to inhaled corticosteroid therapy for asthma. Swallowed topical glucocorticoid therapy is the 
main pharmacotherapy treatment for eosinophilic esophagitis (EoE) and therefore children with EoE are potentially at 
increased risk of AS.
Methods: In this prospective cohort study, we included children and youth <18 years diagnosed with EoE and 
treated with swallowed fluticasone or oral viscous budesonide for more than 1 month. First morning cortisol and low 
dose adrenocorticotropic hormone stimulation test (LDST) were performed 2 weeks following GC discontinuation. AS 
was defined as an abnormal LDST result (cortisol peak <500 nmol/L). We determined the prevalence and duration of 
AS related to swallowed topical GC therapy in EoE by LDST, as well as the diagnostic accuracy of first morning cortisol 
compared to LDST.
Results: Of 29 participants enrolled, 26 (89.7 %) received oral viscous budesonide and 3 (10.3 %) received swallowed 
fluticasone. Nineteen (65.5 %) participants had AS. Median duration of AS was 43 weeks. Five (17.2 %) participants had 
persistent AS at 12 months. There were no identifiable risk factors for the development of AS. First morning cortisol 
was highly specific but had poor sensitivity for detection of AS.
Conclusions: The majority of children with EoE had AS after discontinuation of swallowed topical GC therapy. Stress 
steroids should be considered in children treated with swallowed topical GC therapy for EoE, even after GC discon-
tinuation, to prevent possible adrenal crisis.
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Background
Adrenal suppression (AS), a potential side effect of glu-
cocorticoid (GC) therapy, is the most common form of 
secondary adrenal insufficiency [1]. Significant morbid-
ity and mortality related to AS in patients treated with 
inhaled corticosteroids (ICS) has been well described in 
the asthma population [2, 3].
The swallowed portion of ICS that escapes first pass 
inactivation by the liver may lead to systemic side effects 
[4]. Swallowed fluticasone or viscous budesonide are the 
mainstays of pharmacotherapy in eosinophilic esophagi-
tis (EoE) [5]. Children treated for EoE are therefore 
potentially at increased risk of AS and its associated mor-
bidity. Guidelines exist for screening and management of 
potential AS in children treated with ICS for asthma [6]. 
However there are currently no guidelines addressing the 
risk in children receiving swallowed ICS for EoE.
AS occurs due to negative feedback inhibition when 
the hypothalamic-pituitary-adrenal axis is exposed to 
exogenous GCs, resulting in decreased cortisol produc-
tion [7]. Symptoms of AS are often non-specific and may 
go unrecognized until an adrenal crisis is precipitated 
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by physiologic stress such as illness, surgery, injury, or 
anesthesia [1]. Adrenal crisis presents as hypotension, 
hypoglycemia, shock, decreased consciousness, seizure 
or even death [7] and has been well described related to 
GC therapy for asthma and malignancy in children [2, 8]. 
AS can persist for months to years following discontinu-
ation of GC therapy [9, 10]. Prevention of adrenal crisis 
requires recognition of AS and administration of GCs 
during times of physiological stress [1].
We conducted a prospective cohort study to determine 
the prevalence and duration of AS in children with EoE. 
In addition, we determined whether first morning corti-
sol was a sensitive and specific screening test for AS in 
the population, or whether a low dose ACTH stimulation 
test (LDST) was necessary to make the diagnosis. We 
also sought to determine risk factors for the development 
of AS, and the diagnostic accuracy of first morning corti-




We conducted a prospective observational cohort study 
in the EoE clinic at the Children’s Hospital of Eastern 
Ontario (CHEO), Ottawa, Canada.
The study was approved by the Research Ethics Board 
of the Children’s Hospital of Eastern Ontario (CHEO 
REB Protocol No: 11/181X). Informed consent/assent 
was obtained, as appropriate.
Participants
We included children and youth  <18  years diagnosed 
with EoE treated with swallowed fluticasone or oral vis-
cous budesonide for more than 1 month, over a 2 year 
period from 2011 to 2013. All included participants 
were diagnosed as per standard clinical and histologi-
cal criteria [5]. They were refractory to proton pump 
inhibitor (PPI) therapy, and were symptomatic with 
dysphagia, abdominal pain, heartburn, or other symp-
toms consistent with EoE. All included participants had 
biopsy-proven EoE, defined as >15 eosinophils per high-
powered field (hpf) from mucosal biopsies in any region 
of the esophagus obtained during esophagogastroduo-
denoscopy. Participants were followed for a minimum 
of 12 months or until August 2014 and were excluded if 
they had known adrenal insufficiency unrelated to GC 
therapy including ACTH deficiency due to hypothalamic 
or pituitary gland abnormalities, or a primary adrenal 
disorder. Participants who had received continuous oral 
or intravenous GC therapy for more than 2 weeks during 
the 6 month period preceding study enrollment were also 
excluded. The treatment protocol evaluated in our study 
represented a new standard of care for our EoE clinic 
and therefore all patients meeting the above criteria were 
enrolled consecutively.
Treatment protocol
Participants were treated with oral viscous budeson-
ide 1 mg (for children <5 feet tall) or 2 mg (for children/
youth ≥5 feet tall) mixed with Splenda® to form a vis-
cous suspension (approximately 0.5  mg/2  mL) [11]. If 
they declined viscous budesonide, they were offered 
therapy with swallowed fluticasone. Fluticasone dose was 
125 mcg/puff (for children <5 feet tall) or 250 mcg/puff 
(for children/youth  ≥5 feet tall), swallowed once daily. 
Treatment at full dose was continued for 3 months, and 
then tapered by giving the same dose every other day for 
1  month, followed by discontinuation of the swallowed 
topical GC therapy.
As part of our standard clinical practice guidelines, all 
patients diagnosed with AS are instructed to administer 
stress doses of GCs until resolution of AS (normalization 
of the LDST). Management of AS is outlined in Appen-
dix Table 3.
Assessment of adrenal axis functioning
A first morning cortisol level (drawn between 08:00 and 
09:00) and LDST were arranged for 2  weeks (±3 days) 
following the final swallowed topical GC dose. First 
morning cortisol levels and LDST were performed in 
the Medical Day Unit at CHEO. If abnormal on initial 
testing, LDST was repeated 2 months following discon-
tinuation of swallowed topical GC therapy, and every 
3 months thereafter until resolution of AS (normalization 
of LDST). The duration of AS was defined as the time 
from the initial abnormal LDST to normalization of the 
LDST (>500 nmol/L).
Laboratory investigations
Serum cortisol levels were measured by competitive 
binding immunoenzymatic assay (Beckman Coulter). 
First morning cortisol levels were measured in the serum 
on samples obtained between 08:00 and 09:00. A cortisol 
value of >185 nmol/L was considered to be normal; this 
normal value corresponds to our hospital biochemistry 
laboratory normal range for morning cortisol.
To perform the LDST, a peripheral intravenous line 
was established and 1 mcg of IV cosyntropin was admin-
istered (Cortrosyn, Amphastar Pharmaceuticals Inc.). 
Sampling of serum cortisol levels was done at 15, 30 and 
60 min after cosyntropin administration. A normal LDST 
result was defined as a cortisol level peak  >500  nmol/L 
[12, 13]. AS was defined as an abnormal LDST (cortisol 
peak <500 nmol/L) [12, 13].
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Statistical analysis
Descriptive statistics were calculated and reported as 
medians with interquartile range (IQR) or means with 
standard deviation (SD) where appropriate. Diagnostic 
accuracy of first morning cortisol was reported com-
pared to the reference standard LDST (using 500 nmol/L 
as the cutoff value) by calculating sensitivity, specificity, 
positive predictive value (PPV), negative predictive value 
(NPV), and likelihood ratios (LR) with 95  % confidence 
intervals (CI). Agreement between first morning cortisol 
and LDST to identify those with AS was calculated using 
Cohen’s Kappa statistic (±standard error). The receiver 
operating characteristic (ROC) curve was used to deter-
mine the best cutoff of first morning cortisol to differen-
tiate those with normal and abnormal LDST. Statistical 




Characteristics of enrolled participants are outlined 
in Table  1. Thirty-three patients met the study inclu-
sion criteria and consented to enrollment; 29 patients 
were enrolled (Fig.  1). Of the 29 study participants, 26 
(89.7 %) were treated with oral viscous budesonide, and 
three (10.3  %) were treated with swallowed fluticasone. 
Thirteen participants (44.8 %) were receiving other forms 
of GCs (Table  1). None of the additional forms of GCs 
were systemic.
Initial testing for adrenal suppression
Two weeks following discontinuation of GC therapy, 19 
(65.5 %) participants were found to have AS, as defined 
by a LDST peak  <500  nmol/L on initial testing (Fig.  2). 
Of those, 11 of 19 (57.9 %) had a borderline LDST result 
(peak cortisol 450–499  nmol/L), and 8 of 19 (42.1  %) 
had a LDST peak  <450  nmol/L (Fig.  1). All but one of 
the participants with AS were treated with budesonide. 
On exploratory univariate analysis, there were no sig-
nificant predictors of AS, including concomitant ICS use 
(Table 2).
Five of the 19 participants (26.3 %) with confirmed AS 
had an abnormal first morning cortisol (<185  nmol/L) 
(Fig.  3). There was only slight agreement between 
Table 1 Descriptive characteristics of study cohort
EoE eosinophilic esophagitis, ICS inhaled corticosteroids, IQR interquartile range, 
GC glucocorticoid, N number, SD standard deviation, y years
a A diagnosis of allergy was made based on skin prick testing for food and/or 
environmental allergies by an allergist
b Most participants had a history of infrequent ICS use during inter-current 
infection only. Two participants were being actively treated with daily moderate 
ICS doses (Flovent 250 mcg daily and Alvesco 400 mcg daily)
Characteristic
Total number of patients analyzed 29
Female, N (%) 7 (24.1)
Median age (y) at diagnosis with EoE (IQR) 13.2 (6.4)
Median age (y) at study enrollment (IQR) 14.1 (4.6)
Features of GC therapy
 Duration of GC therapy (days ± SD) 104.6 ± 23.7
 Oral viscous budesonide, N (%) 26 (89.7)
 Swallowed fluticasone, N (%) 3 (10.3)
Concomitant conditions, N (%)
 Asthma 21 (72.4)
 Allergiesa 27 (93.1)
 Eczema 10 (34.5)
Additional forms of GC therapy, by patient, N (%)
 Total number of patients receiving additional forms 13 (44.8 %)
 Inhaled corticosteroidsb 11 (37.9 %)
 Intranasal 1 (3.4 %)
 Topical 2 (6.9 %)
Fig. 1 Study flow diagram
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first morning cortisol and LDST to define AS (Kappa 
0.198  ±  0.09, P  =  0.092). The diagnostic accuracy of 
abnormal first morning cortisol (<185  nmol/L) to iden-
tify AS (defined by an abnormal LDST) was as follows: 
sensitivity 26.3 % (95 % CI 45.7–81.4 %), specificity 100 % 
(95 % CI 65.5–100 %), PPV 100 % (95 % CI 46.3–100 %), 
NPV 37.5  % (95  % CI 19.6–59.2  %), LR+  infinite, LR− 
0.75 (95 % CI 0.58–0.97). As defined by the ROC curve, 
the best cutoff of first morning cortisol to define AS was 
323  nmol/L, which differentiated AS participants from 
those without AS with sensitivity 70.0 % (95 % CI 45.7–
87.2  %), specificity 77.8  % (95  % CI 40.2–96.1  %), PPV 
87.5 % (95 % CI 60.4–97.8 %), NPV 53.8 % (95 % CI 26.1–
79.6 %), LR+ 3.15 (95 % CI 0.90–11.05), LR− 0.39 (95 % 
CI 0.19–0.80).
Longitudinal testing for sustained adrenal suppression
Median duration of AS was 42.7 (IQR 11.1–60.6) 
weeks. AS lasted  >365  days in at least 5 of 19 (26.3  %) 
participants; all of which had a LDST peak <450 nmol/L. 
Details of longitudinal testing are depicted in Fig.  1. 
There were no reported cases of adrenal crisis during the 
study period.
Availability of data and materials
An additional Excel file shows the dataset on which the 
conclusions of the manuscript rely (Additional file 1).
Discussion
The findings of our study demonstrate that children are 
at significant risk of prolonged AS following treatment 
with swallowed topical glucocorticoids for the treatment 
of EoE. Almost two-thirds of the children in our study 
had AS 2 weeks following treatment with a median dura-
tion of 42 weeks; several had persistent AS beyond 1 year. 
Our prospective study provides an important contribu-
tion to our understanding of AS in the EoE population, 
demonstrating that this potential side effect is not only 
a concern while on treatment, but continues following 
discontinuation of swallowed glucocorticoid therapy. In 
addition, we demonstrated that first morning cortisol 
was not a sensitive test for AS when compared with the 
LDST.
Previous studies examining AS in children treated 
with swallowed topical GC have resulted in mixed 
conclusions. A national surveillance study of sympto-
matic AS from any form of GC reported that 2 of 46 
children were treated with swallowed topical GC, sug-
gesting that the EoE population might be at increased 
risk [14]. A recent retrospective study also suggested 
that children who were being actively treated with 
swallowed budesonide for EoE were at increased risk 
of AS [15]. Our study confirmed these warnings. In 
contrast to the previous study [15], we tested 2 weeks 
after discontinuation of topical GC therapy to rule 
out acute transient AS that would be expected while 
receiving GC therapy.
Fig. 2 Peak cortisol level on ACTH stimulation test in adrenal sup-
pression (AS) vs no adrenal suppression (NO AS) group
Table 2 Potential predictors of adrenal suppression
AS adrenal suppression, BMI body mass index, GC glucocorticoid, ICS inhaled corticosteroids, IQR interquartile range, N number
a Fisher’s Exact test
b Wilcoxon-Mann–Whitney test
c T test (equal variances not assumed)
No AS AS p value
Female sex (N,  %) 3/10 (30 %) 4/19 (21.1 %) 0.66a
Age (median, IQR) 15.15 (4.75) 13.81 (4.66) 0.31b
Duration of GC therapy (days) 113.5 ± 30.44 99.8 ± 18.44 0.22c
BMI 18.2 ± 2.54 19.3 ± 3.15 0.33c
Concurrent use of ICS therapy (intermittent or continuous) 2/10 (20 %) 9/19 (47.3 %) 0.23a
Concurrent use of ICS therapy (continuous only) 1/10 (10 %) 5/19 (26.3 %) 0.63a
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Our findings differed from a recent prospective study 
that examined 14 children receiving swallowed topical 
GCs concluding that there was no significant effect on 
the adrenal axis [16]; the conflicting results were likely 
secondary to the testing modality chosen to define AS. 
Morning cortisol was used to evaluate the HPA axis [15]; 
we demonstrated that this test has very poor sensitivity 
for AS indicating that dynamic testing should be consid-
ered instead.
Our findings suggest that an abnormal first morn-
ing cortisol (<185 nmol/L) is highly specific for adrenal 
suppression in the EoE population treated with swal-
lowed topical GC therapy but that sensitivity is poor. 
The cutoff of 185  nmol/L is significantly higher than 
cutoffs previously reported in the literature [17–19] and 
likely reflects a higher pre-test probability of AS in the 
EoE population. While it is important for clinicians to 
be aware that cortisol thresholds vary slightly between 
platforms and cannot be directly compared, it is unlikely 
that this accounts for our results [18, 20]. Our findings 
are consistent with previous studies in other popula-
tions, suggesting that the LDST with sensitivity and 
specificity around 90 % [12, 21], is required in the evalu-
ation of AS unless first morning cortisol values are very 
high or very low [19, 22].
Potential systemic side effects of ICS, including AS, 
occur when the swallowed portion escapes inactivation 
by first-pass metabolism in the liver and enters the sys-
temic circulation [4]. A recent study in adults with EoE 
concluded that active disease may result in reduced elim-
ination of budesonide via CYP3A, compared to healthy 
adults, suggesting a possible increased risk of AS in the 
EoE population [23].
Adrenal crisis during surgery and illness in patients 
with adrenal insufficiency who have not received stress 
doses of GC therapy is well documented [2, 8]. General 
anesthesia is also a potential stressor and is a consid-
eration in patients with EoE undergoing gastrointestinal 
endoscopy. A recent CSACI position statement provides 
an approach to screening and management of potential 
AS in children treated with ICS for asthma [6]. Our 
study suggests that clinicians should be aware of the 
potential for AS in all children being treated with swal-
lowed topical corticosteroids and consider GC stress 
dosing for significant physiological stress until sig-
nificant abnormalities on LDST are ruled out. If there 
are unexplained non-specific symptoms (i.e. fatigue, 
malaise, nausea, vomiting, abdominal pain, headache) 
or poor growth, then testing of the HPA axis and con-
sultation with a pediatric endocrinologist should be 
sought. In addition, a pediatric endocrinologist should 
be consulted for individuals with prolonged AS based 
on LDST.
A possible limitation of our study is the absence of 
LDST prior to initiation of swallowed topical GC ther-
apy. Almost half of the study population received other 
forms of GC therapy for treatment of asthma, eczema 
and allergic rhinitis; yet none were receiving regular 
high doses of ICS. Fifty three percent of children with 
AS in our study did not receive concomitant GC therapy, 
demonstrating that swallowed topical GCs can cause 
AS independently. Although concomitant GC use was 
not demonstrated to be a risk factor for AS, our study 
may not have been powered to detect this. The use of the 
lowest effective doses of all forms of GC may help in the 
prevention of AS [3].
This study was limited by the small number of enrolled 
participants; the univariate analysis of risk factors for 
AS was exploratory only as our study may not have been 
powered to detect predictors. While 27.6 % of our chil-
dren had significantly abnormal LDST results, 57  % of 
children in the AS group had a “borderline” cortisol peak 
on LDST (450–499  nmol/L), the clinical significance of 
which is difficult to interpret. To our knowledge, there is 
no literature that has examined the risk of symptomatic 
AS in individuals with mildly abnormal LDST. As such, 
all participants with documented AS were treated with 
stress doses of GC therapy for illness, surgery or injury as 
per standard of care [1].
In conclusion, almost two-thirds of the children/youth 
in our EoE cohort had evidence of AS detected by LDST 
following discontinuation of swallowed topical GC ther-
apy. Twenty seven percent of the subjects demonstrated 
significant abnormalities on testing, indicating that AS 
is a true concern in EoE. When present, AS was persis-
tent and prolonged. Unrecognized AS can lead to adrenal 
Fig. 3 First morning cortisol value in adrenal suppression (AS) vs no 
adrenal suppression (NO AS) group
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crisis with significant morbidity and even mortality [1, 2]. 
We recommend consideration of GC stress dosing dur-
ing significant physiological stress (moderate to severe 
illness or injury, general anesthesia or surgery) in chil-
dren/youth being treated with swallowed topical GC for 
EoE both during and after discontinuation of their swal-
lowed topical GC therapy and until significant abnor-
malities on LDST are ruled out. Borderline results on 
LDST need to be evaluated on an individual basis; future 
study addressing the risk in these patients is needed. This 
study highlights the essential need for further education 
of EoE patients, families and the health care team about 
the symptoms of AS and the management of illness in the 
context of AS.
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Appendix
See Table 3.
Table 3 Management of AS—recommendations given to patients/families of children with EoE at CHEO
BID twice daily, TID three times daily, ER emergency department, IV intravenous, q am daily morning
Stress dosing recommended to all patients until normalization of LDST
 Mild illness or fever 20 mg/m2/day hydrocortisone equivalent, divided BID or TID
 Fever >38.5 or vomiting 30 mg/m2/day hydrocortisone equivalent, divided TID
 Severe illness or injury OR unable to tolerate oral GC during illness ER for IV GC therapy
 Surgery or procedure with anesthesia Endocrinology consulted for IV GC dosing
Patients with first morning cortisol <185 nmo/L
 Daily glucocorticoid therapy 10 mg/m2/day q am
 Illness/surgery/injury Stress dosing as outlined above
Additional file
Additional file 1. Eosinophilic esophagitis adrenal suppression dataset.
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